Dicerna to Present at Two March Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences:

• Cowen & Company 36th Annual Health Care Conference. Dicerna’s presentation will take place on Wednesday, March 9th, 2016, at 11:20 a.m. ET at the Boston Marriott Copley Place in Boston, MA.
• The 23rd Annual Future leaders in the Biotech Industry Conference. Dicerna’s presentation will take place on Friday, March 11th, 2016, at 11:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York City.

A live webcast of each presentation can be accessed by visiting "Events & Presentations" in the Investors and Media section on the Company's website at www.dicerna.com. An archived replay of the webcasts will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005838/en/

For Dicerna Pharmaceuticals, Inc.
Investor Contact:
Westwicke Partners
Peter Vozzo, 443-213-0505
[email protected]
or
Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
[email protected]

Source: Dicerna Pharmaceuticals, Inc.

You May Also Be Interested In

• TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'
• TechMediaBreaks – Solidion Technology Inc. (NASDAQ: STI) Closes $35 Million Private Placement 
• Atropos Health Expands Partnership with Databricks with the Launch of the Atropos Evidence Agent MCP on Databricks Marketplace